EAE Induction by Active Immunization in C57BL/6 Mice

Similar documents
Type: Embedded within the selected substance, indicated when creating the substance.

Vertebrate Animal Use Protocol for Research or Testing

University Animal Care Committee (UACC) Standard Operating Procedure (SOP) Rodent Health Surveillance Program

Intravitreal and sub-retinal injections of plasmid DNA and electroporation in P0 pups

Custom Antibodies Services. GeneCust Europe. GeneCust Europe

VACCINE DELIVERY USING THE NEMAURA SOLID DOSE INJECTOR

Policies Concerning Survival Surgery of Mice

RODENT COLONY HEALTH MONITORING

Policy 19 Fluid Administration and Collection in Rodents Version 1.0 Approval Date: 12/12/12

QIAfilter Plasmid Midi Kit (Cat #: 12243)

Rabbit Welfare Transportation and Processing Audit Tool and Standards

UltraClean Midi Plasmid Prep Kit

Foreign serum-induced bile duct lesion (BDL) in athymic BALBIc nude mice

Adoptive Transfer of Isolated Bone Marrow Neutrophils Jimena Tosello Boari 1 and Eva Acosta Rodríguez 2*

in vivo-jetpei DNA & sirna delivery reagent

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE

Improving intravenous injection in black mice

Supplementary File 3: DNA and RNA isolation

Initial Reporting of Animal Welfare Concern to the Institution

EGFR (Phospho-Ser695)

Annual statistical report for animals used in Ireland under scientific animal protection legislation

The presenter declare no conflict of interest This work was partly supported by Selecta Bioscience

Current Operator Load vs. 85% of TAKT

SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS.

PRINCIPLES AND GUIDELINES FOR THE CONDUCT OF MICROBIOLOGICAL RISK ASSESSMENT CAC/GL Adopted Amendments 2012, 2014.

obtained from the infected and treated tissues, Fleming's2 technic of hemolytic streptococcus B. Immediately following the infection, 1.0 ml.

Neutrophil/Monocyte Respiratory Burst Assay Kit

Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex

VENTO WIFI DRONE WITH LIVE STREAMING CAMERA

Genlantis A division of Gene Therapy Systems, Inc Telesis Court San Diego, CA USA Telephone: or (US toll free)

A simple device for injecting small volume (5-100 micro l) of liquid in small laboratory animals

DAIRY ANIMAL PRODUCTIVITY ENHANCEMENT PROGRAM With HERDMAN

Enoxaparin (Lovenox )

PORTABLE DANCE FLOOR General care & laying instructions

TaKaRa MiniBEST Viral RNA/DNA Extraction Kit Ver.5.0

HFM Asset Management Contractor Induction Queens Riverside Apartments

BakeMax Dough Mini Moulder BMMDM02

xcelligence Immunotherapy Kit - B Cell Killing Assay ASSAY MANUAL

Discover TruPRP. PRP the way you want it.

Catalog # Product Size PRIME-XV Hematopoietic Cell Basal XSFM 500 ml (liquid) Additional package sizes are available at request

A. Purpose and applicability B. Legal principles and formal aspects of the reports... 2

Selecting Homozygous Transformed Plants

General Guidelines for Users and Visitors to NTU. Animal Research Facility

AIR QUALITY IN SWINE-FINISHING BARNS 1

Freedom One-Piece Barrier Free Showers Installation Instructions

INOS. Colorimetric Cell-Based ELISA Kit. Catalog #: OKAG00807

special offers from your protein biology resource

Generation of Mouse Spinal Cord Injury Oneil G. Bhalala *, Liuliu Pan, Hilary North, Tammy McGuire and John A. Kessler

Instructions for use

Yellow Fever Vaccine (Live) is a freeze-dried preparation of the 17D strain of yellow fever virus grown in fertilised hen eggs.

FULL PAPER Identification of epistasis through a partial advanced intercross reveals three arthritis loci within the Cia5 QTL in mice

AXIS II RC DRONE WITH CAMERA

The relationship between lameness and milk yield in. Comparison of milk yield in dairy cows with different degrees of lameness

DAIRY ANIMAL PRODUCTIVITY ENHANCEMENT PROGRAM With HERDMAN

BIOO LIFE SCIENCE PRODUCTS

EQUIVALENCY STUDY: FETAL TISSUE GENERATION FOR DISSECTION MICROSCOPY PRODUCT IDENTIFICATION

GeNei TM Transformation Teaching Kit Manual

celldatasci.com/rnastorm RNAstorm RNA Isolation Kit for FFPE Tissue Samples Sample Kit (20 extractions)

BEST PRACTICES IN MOUSE TISSUE SAMPLE PREPARATION FOR RNA EXTRACTION WITH PRECELLYS EVOLUTION

Cytoplasmic & Nuclear RNA Purification Kit Product # 21000, 37400

LEARN. about. Please see Important Safety Information on pages 3-5 and enclosed full Prescribing Information.

Essential Functions and Physical Demands Analysis

RNA 004 v.003 Assessing the quality of RNA using the Agilent 2100 Bioanalyzer

Water-Water Titration for the MicroCal ITC200

HighPrep Blood & Tissue DNA Kit

NEVER REMOVE THE SAFETY GUARDS

Learn more about why severe RSV disease APPROVED USE

Instruction Manual HT 24 BM-D2400 Homogenizer

Xeno-Free Systems for hesc & hipsc. Facilitating the shift from Stem Cell Research to Clinical Applications

Agenda. Highlights. Q3 financials. Beta-Glucans. Enzymes. Outlook. advanced wound care. molecular testing

Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines

Tips for sequencing DNA

Inspection Checklist for NIH BL3 Laboratories (7 CFR 331; 9 CFR 121; 42 CFR 73; NIH Guidelines)

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician.

dronium TWO AP DRONE with camera

Continuous Protein Production Protocol for Wheat Germ Cell-free Protein Expression by Dialysis Method

ReproRNA -OKSGM is a non-integrating, self-replicating RNA-based reprogramming vector for generating induced pluripotent stem (ips)

HT RNA LabChip Kit, Version 2 LabChip GX/GXII User Guide

Data Sheet. PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit Catalog # Size: 96 reactions

ANTIBODY IMMUNOGENICITY

VDL106.3 LARGE-SCALE AMPLIFICATION AND PURIFICATION OF ADENOVIRAL VECTOR

Final Approval: October 2010 Effective: October 2010 Next Review Date: August 2012

Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines

In-Cell Western Kits I and II

TITLE: LIVE/DEAD VIABILITY FOR CLINICAL SAMPLES

Western BLoT Ultra Sensitive HRP Substrate

Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients

Today, we will discuss the importance of accident investigation, how to talk to witnesses, what questions to ask when evaluating an accident scene,

KCC Path-Core Page 1 of 5

IB Biology Higher Level. Lab Report

P08 P14 P19 TRANSDERMAL DELIVERY & MICRONEEDLES TRANSDERMAL DELIVERY USING NATURAL MOISTURISING FACTOR COMPONENTS

K364. Fitting Kit. Fitting Instructions for Basic Carrier. x 6 x 1 x 1 x 2. x 6 x 2 x 2 x 2. x 1 x 1. Revision No: 5C 1

SCREW PILE APPLICATION SHEETS

Transforming E. Coli with pglo Plasmids

ab Hypoxic Response Human Flow Cytometry Kit

**MATERIAL SAFETY DATA SHEET**

Biosafety Protocol. Biodesign Swette Center for Environmental Biotechnology Standard Operating Procedures

Transcription:

Recommended protocol for use with Hooke Kit MOG 35-55/CFA Emulsion PTX (EK-0110, EK-0112, EK-0113, EK-0114, or EK-0115). Summary C57BL/6 mice develop chronic paralysis after immunization with MOG 35-55 peptide emulsified in Complete Freund s Adjuvant (CFA). Mice develop EAE 8-14 days after immunization and stay chronically paralyzed for the duration of the experiment (typically, mice are observed for 30-40 days). Around 25% of the mice show exacerbation of EAE symptoms after initial partial recovery. This usually occurs 20-27 days after immunization. Background biology The kit consists of two components, each delivered in separate pre-filled syringes MOG 35-55 in CFA emulsion, and pertussis toxin (PTX) in PBS. The emulsion provides antigen needed to expand and differentiate MOG-specific autoimmune T cells. Tissue dendritic cells pick up the antigen and take it to the draining lymph nodes, where priming of T cells takes place. Pertussis toxin enhances EAE development by providing additional adjuvant. PTX injection affects cell trafficking, development of Th17 cells and integrity of the bloodbrain barrier. It is not clear which of these effects influence EAE development. Kit selection Cat # EK-0113 EK-0110 EK-0112 EK-0114 EK-0115 PTX dose 1x 1.5x 2.5 3.75x 5x Many factors influence EAE disease susceptibility and the pertussis toxin (PTX) dose required. These include mouse age, strain, breeder, and colony, as well as mouse stress. Even with identical mice and reagents, EAE disease can vary considerably from lab to lab. 439 South Union Street Tel +1 617 475 5114 Building 2, Suite 210 http://hookelabs.com Fax +1 617 395 1352 Lawrence, MA 01843 USA info@hookelabs.com

Each Hooke Kit contains different doses of PTX. We recommend that new customers begin by running 10 mice with our strongest Hooke Kit (EK-0115). We can recommend the best Hooke Kit for you based on the EAE incidence and average severity in these mice. Even using optimized reagents, our testing shows that Taconic mice develop somewhat more consistent EAE than Jackson mice. Taconic mice will have a more uniform time of onset and maximum severity score. With a given Hooke Kit, older mice generally develop more severe disease and more uniform disease onset. Materials needed Qty Description 1 Hooke Kit MOG 35-55/CFA Emulsion PTX (EK-0110, EK-0112, EK-0113 or EK-0114 or EK-0115) 10 C57BL/6 mice, females At least 9 weeks old (10 weeks or older recommended) (Taconic Farms model B6-F or Jackson Laboratory strain C57BL/6J) Preparation Minimizing mouse stress is very important to successful EAE induction stress reduces EAE susceptibility in mice. Mice should be housed in a quiet environment, without excessive noise or vibration. Static cages are preferred to some ventilated cages; airflow in some types of ventilated cages may increase mouse stress. It is best to perform all procedures in the mouse room, instead of moving mice to a separate procedure room. Moving mice on carts contributes to stress. Avoid excessive handling of mice; handle mice gently at all times. Use of anesthesia is not necessary or recommended. If anesthesia must be used per veterinary requirements, we recommend inhaled anesthesia to minimize stress. Method Mice should be acclimated at your facility for at least 7 days before immunization. Subcutaneous injection technique is important to successful EAE induction. (These procedures are drafted for right-handed injection; reverse if injecting with the left hand.) 2008-2009 Hooke Laboratories, Inc. Page 2 of 7

1. Grip mouse tail with finger and thumb of right hand (figure). 2. Restrain mouse against cage with three remaining fingers of right hand (figure). 3. With left hand, restrain mouse with two fingers behind head (figure). 4. Using right hand, inject mouse subcutaneously on upper back with 0.1 ml of emulsion (syringe with white content; figure). Keep the needle inserted into the subcutaneous space for 10 to 15 seconds to avoid leakage of the emulsion. Alternatively, a light pull on the syringe plunger will prevent leakage. 5. Using a similar technique, inject mouse subcutaneously on lower back with 0.1 ml of emulsion (figure). Again, keep the needle inserted into the subcutaneous space for 10 to 15 seconds or lightly pull on the syringe to avoid leakage. Repeat (1 5) for all mice. 6. Within 2 hours of injection of the emulsion, intraperitoneally inject the first dose of pertussis toxin (syringe with clear content). Inject 0.1 ml per mouse. 7. 22-26 hours after injection of the emulsion, intraperitoneally inject the second dose of pertussis toxin into the mice; inject 0.1 ml of pertussis toxin (syringe with clear filling) into each mouse. 8. Check mice for signs of EAE daily (see EAE scoring), starting on day 7 after the immunization. 9. As soon as the first signs of paralysis occur, provide mice with food pellets and wet food on the floor of the cage, and easily accessible water. Transgel (Charles River Laboratories) may be used as a source of water during the most severe paralysis. 2008-2009 Hooke Laboratories, Inc. Page 3 of 7

All mice will develop obvious bumps of emulsion at the injection sites 2 to 4 days after injection. In some mice, alopecia will develop at the site of injection 5 to 7 days after injection. In most mice, the emulsion will remain at the site of injection for the duration of the experiment (~30 days). Approximately 10% to 40% of the mice will clear the emulsion by developing skin ulcers at injection sites. Most of the time, these ulcers do not require treatment they usually heal in a few days and scars form. If concerned, consult attending veterinarian. Antibiotic ointment may be applied. EAE development does not correlate with mice clearing or not clearing emulsion from the injection site. 2008-2009 Hooke Laboratories, Inc. Page 4 of 7

EAE Scoring Typically, EAE is scored on scale 0 to 5: Score Clinical Observations 0 No obvious changes in motor functions of the mouse in comparison to non-immunized mice. When picked up by the tail, the tail has tension and is erect. Hind legs are usually spread apart. When the mouse is walking, there is no gait or head tilting. 1 Limp tail. When the mouse is picked up by the tail, instead of being erect, the whole tail drapes over your finger. 2 Limp tail and weakness of hind legs. When mouse is picked up by tail, legs are not spread apart, but held closer together. When the mouse is observed when walking, it has a clearly apparent wobbly walk. 3 Limp tail and complete paralysis of hind legs (most common). OR, Limp tail with paralysis of one front and one hind leg. OR, ALL of: Severe head tilting, Walking only along the edges of the cage, Pushing against the cage wall, Spinning when picked up by the tail. 4 Limp tail, complete hind leg and partial front leg paralysis. Mouse is minimally moving around the cage but appears alert and feeding. Usually, euthanasia is recommended after the mouse scores level 4 for 2 days. When the mouse is euthanized because of severe paralysis, score of 5 is entered for that mouse for the rest of the experiment. 5 Complete hind and complete front leg paralysis, no movement around the cage. OR, Mouse is spontaneously rolling in the cage. OR, Mouse is found dead due to paralysis. If mouse is alive, euthanize the mouse immediately if it scores 5. Once mouse is scored 5, the same score is entered for all the days for the rest of the experiment. 2008-2009 Hooke Laboratories, Inc. Page 5 of 7

Most researchers also give mice in-between scores (i.e. 0.5, 1.5, 2.5, 3.5) when the clinical picture lies between two defined scores. Expected Results EAE will be consistently induced in 90-100% of the mice, with onset of paralysis between 8 and 14 days after immunization, and mean maximum score of 2-3. Daily dosing of mice with a potential therapeutic often delays the onset of EAE and decreases severity of EAE due to stress of the procedures. Careful handling of the mice will minimize these effects. To reduce effects of stress, we recommend sham dosing, 7 and 4 days before immunization of the mice. The following illustrates typical results: Exp # Mice/group Age at immunization Mean maximum score ± SD Day of onset ± SD Disease incidence 1 10 10 weeks 3.25 ± 0.49 10.9 ± 3.9 100 % 2 10 10 weeks 3.45 ± 0.60 10.1 ± 1.5 100 % 3 8 9 weeks 3.25 ± 0.38 12.1 ± 1.6 100 % Data are from three independent experiments using Hooke Kit MOG 35-55/CFA Emulsion PTX (EK-0110), with Taconic mice. Troubleshooting Successful induction of EAE requires low-stress mouse handling and husbandry procedures, good injection technique (as recommended above), use of appropriate 2008-2009 Hooke Laboratories, Inc. Page 6 of 7

mice, and good quality, stable, antigen emulsion together with the correct amount of pertussis toxin. If you have difficulty inducing EAE, check the following: Mice should be acclimated for 7 days to your lab before starting. Use female mice at no younger than 9 weeks old. (10 weeks or older recommended.) Follow recommended injection procedure (see above). Avoid excessive noise or vibration. Avoid excessive handling of mice. Handle mice gently. Try to do all procedures in the mouse room. Avoid moving mice on carts. Static cages are preferred to (some) ventilated cages. Avoid use of anesthesia if possible. If anesthesia must be used, we recommend inhaled anesthesia. References Mendl I et al, Eur J Immunol 25:1951, 1995 Marusic S et al, J Exp Med 202:841, 2005 Thakker P et al, J Immunol 178:2589, 2007 Version: 2009-01 2008-2009 Hooke Laboratories, Inc. Page 7 of 7